Ken Griffin 89bio, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in 89bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 34,100 shares of ETNB stock, worth $270,754. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,100

Previous 20,100 69.65%

Holding current value

$270,754

Previous $161,000 56.52%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$7.36 - $9.66 $3.29 Million - $4.32 Million	447,645 Added 21.22%	2,556,727 $18.9 Million
Q2 2024 Aug 14, 2024	BUY	$7.31 - $10.9 $3.94 Million - $5.88 Million	539,540 Added 34.38%	2,109,082 $16.9 Million
Q1 2024 May 15, 2024	SELL	$8.13 - $13.77 $4.95 Million - $8.38 Million	-608,797 Reduced 27.95%	1,569,542 $18.3 Million
Q4 2023 Feb 14, 2024	BUY	$6.66 - $16.03 $4.49 Million - $10.8 Million	674,330 Added 44.84%	2,178,339 $24.3 Million
Q3 2023 Nov 14, 2023	BUY	$15.06 - $19.41 $6.32 Million - $8.15 Million	419,653 Added 38.7%	1,504,009 $23.2 Million
Q2 2023 Aug 14, 2023	SELL	$14.15 - $22.03 $11.6 Million - $18.1 Million	-819,999 Reduced 43.06%	1,084,356 $20.5 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $10 Million - $16.2 Million	954,043 Added 100.39%	1,904,355 $29 Million
Q4 2022 Feb 14, 2023	SELL	$5.52 - $12.73 $1.02 Million - $2.34 Million	-184,110 Reduced 16.23%	950,312 $12.1 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $213,870 - $495,726	70,818 Added 6.66%	1,134,422 $6.57 Million
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $1.36 Million - $2.61 Million	650,485 Added 157.46%	1,063,604 $3.42 Million
Q1 2022 May 16, 2022	BUY	$3.45 - $14.99 $492,366 - $2.14 Million	142,715 Added 52.78%	413,119 $1.56 Million
Q4 2021 Feb 14, 2022	SELL	$11.15 - $19.66 $216,867 - $382,387	-19,450 Reduced 6.71%	270,404 $3.53 Million
Q3 2021 Nov 15, 2021	SELL	$14.91 - $21.31 $2.97 Million - $4.24 Million	-198,911 Reduced 40.7%	289,854 $5.68 Million
Q2 2021 Aug 16, 2021	SELL	$17.42 - $28.0 $332,756 - $534,856	-19,102 Reduced 3.76%	488,765 $9.14 Million
Q1 2021 May 17, 2021	BUY	$20.22 - $26.73 $362,221 - $478,841	17,914 Added 3.66%	507,867 $12 Million
Q4 2020 Feb 16, 2021	BUY	$23.16 - $28.08 $11.1 Million - $13.5 Million	480,519 Added 5093.48%	489,953 $11.9 Million
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $229,623 - $366,227	9,434 New	9,434 $242,000

Others Institutions Holding ETNB

# of Institutions

158

Shares Held

108M

Call Options Held

73.6K

Put Options Held

1.19M

View Full List

About 89bio, Inc.

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $369M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

More about ETNB

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account